Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Genomic control

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44356   clinical trials with a EudraCT protocol, of which   7382   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    140 result(s) found for: Genomic control. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2015-005838-22 Sponsor Protocol Number: CLIO Start Date*: 2016-07-22
    Sponsor Name:UZLeuven
    Full Title: Circulating tumor DNA guiding (Olaparib) Lynparza® treatment in Ovarian Cancer (CLIO). Establishing the value of a ctDNA-based HRD assay for predicting olaparib response in women with relapsed ovar...
    Medical condition: platinum-sensitive and platinum-resistant relapsed ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002555-10 Sponsor Protocol Number: DS1062-A-U304 Start Date*: 2022-07-21
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cance...
    Medical condition: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004771-40 Sponsor Protocol Number: ML41742 Start Date*: 2020-04-28
    Sponsor Name:Rigshospitalet
    Full Title: ProTarget A Danish Nationwide Clinical Trial on Targeted Anti-Cancer Treatment based on Genomic Profiling
    Medical condition: Eligible patients will have an advanced malignant disease for which standard treatment options are no longer available or feasible and acceptable performance status and organ function.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002734-20 Sponsor Protocol Number: R3918-PNH-1852 Start Date*: 2020-08-07
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: An Open Label, Single Arm Study to Evaluate the Efficacy and Safety of REGN3918 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor Naive or Have Not Recently Re...
    Medical condition: Paroxysmal nocturnal hemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (GB - no longer in EU/EEA) HU (Completed) NL (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000580-14 Sponsor Protocol Number: UC-0105/1501 Start Date*: 2015-05-12
    Sponsor Name:UNICANCER
    Full Title: A single arm, open-label, phase II study to assess the efficacy of rucaparib in metastatic breast cancer patients with a BRCAness genomic signature.
    Medical condition: Patients with progressing metastatic breast cancer pretreated with at least one line of chemotherapy at the metastatic setting.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001430-33 Sponsor Protocol Number: GS-US-365-4237 Start Date*: 2020-05-15
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis
    Medical condition:
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004592-35 Sponsor Protocol Number: 6836 Start Date*: 2010-06-16
    Sponsor Name:Barts Health NHS Trust
    Full Title: A Randomised Stratified Multicentre Phase II Clinical Trial of Single-Agent ADI-PEG 20 (Pegylated Arginine Deiminase) in Patients with Malignant Pleural Mesothelioma.
    Medical condition: Mesothelioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-002731-32 Sponsor Protocol Number: D/P3/21/7 Start Date*: Information not available in EudraCT
    Sponsor Name:Diamyd Medical AB
    Full Title: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults with...
    Medical condition: Type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10045228 Type I diabetes mellitus LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing) DE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) EE (Trial now transitioned) HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001734-17 Sponsor Protocol Number: FuMA Start Date*: 2014-04-23
    Sponsor Name:University of Rome Foro Italico
    Full Title: Short-term effects of testosterone enhantate and gel on neuro-physiological function
    Medical condition: HYPOGONADISM
    Disease: Version SOC Term Classification Code Term Level
    16.1 10014698 - Endocrine disorders 10058359 Hypogonadism PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004158-17 Sponsor Protocol Number: GELTAMO-IMCL-2015 Start Date*: 2016-02-15
    Sponsor Name:GELTAMO (Grupo Cooperativo Español de Llinfoma/Trasplante Autólogo de Médula Ósea)
    Full Title: Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinical forms of Mantle Cell Lymphoma.
    Medical condition: Mantle Cell Lyphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004414-35 Sponsor Protocol Number: IMPRESSNorway Start Date*: 2021-02-19
    Sponsor Name:Oslo University Hospital
    Full Title: Improving public cancer care by implementing precision medicine in Norway
    Medical condition: Patients with a biomarker indicating response to IMP can be included in IMPRESS-Norway. Patients with disease characteristics covered in present indications for the IMP are not eligible.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004931-10 Sponsor Protocol Number: R3918-PNH-2050 Start Date*: 2022-12-27
    Sponsor Name:REGENERON PHARMACEUTICALS, INC.
    Full Title: An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004321-26 Sponsor Protocol Number: 1100.1452 Start Date*: 2006-02-17
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Case-Control Toxicogenomics Study to identify Unique Genetic Polymorphisms in Patients who have experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity within the First 8 weeks of Nev...
    Medical condition: The patient population for this study will be comprised of patients with HIV-1 infection who have taken or are currently taking nevirapine and who have (cases) or have not (controls) experienced sy...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002761-33 Sponsor Protocol Number: R3918-PNH-2022 Start Date*: 2022-05-02
    Sponsor Name:REGENERON PHARMACEUTICALS, INC.
    Full Title: A RANDOMIZED, OPEN-LABEL ECULIZUMAB AND RAVULIZUMAB CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGL...
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Prematurely Ended) FR (Prematurely Ended) PL (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002808-28 Sponsor Protocol Number: OZM-061 Start Date*: 2017-12-29
    Sponsor Name:Princess Margaret Cancer Centre
    Full Title: Olala Trial: A Retrospective/Prospective Analysis of Characterization of the Long-Term Responders on Olaparib in Solid Tumours
    Medical condition: epithelial ovarian cancer (including fallopian tube or peritoneal cancer)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002774-27 Sponsor Protocol Number: DS1062-A-U202 Start Date*: 2021-04-16
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations and Progressed on or After Applicable Targeted Therapy an...
    Medical condition: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Trial now transitioned) HU (Completed) NL (Trial now transitioned) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004486-40 Sponsor Protocol Number: R3918-PNH-2021 Start Date*: 2022-04-04
    Sponsor Name:REGENERON PHARMACEUTICALS, INC.
    Full Title: A RANDOMIZED, OPEN-LABEL, RAVULIZUMAB-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO A...
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2023-000183-65 Sponsor Protocol Number: TTCC-2022-01-RADIAN Start Date*: 2023-08-23
    Sponsor Name:Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC)
    Full Title: Phase Ib/II non-randomized non-comparative two-cohort study of Niraparib and Dostarlimab plus (Chemo)RadIotherapy in Locally-Advanced head and Neck squamous cell carcinoma (RADIAN)
    Medical condition: Locally-Advanced head and Neck squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003058-10 Sponsor Protocol Number: NADEJ201901 Start Date*: 2019-11-21
    Sponsor Name:VÝCHODOSLOVENSKÝ ONKOLOGICKÝ ÚSTAV, a.s.
    Full Title: Prospective, multicentre phase II study of de-escalation of primary chemoradiotherapy of squamous cell carcinoma of oropharynx (OPC) associated with human papilloma virus (HPV)
    Medical condition: Human Papillomavirus oropharyngeal squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001561-32 Sponsor Protocol Number: 201900237 Start Date*: 2020-04-28
    Sponsor Name:University Medical Center Groningen
    Full Title: Dupilumab in adults with severe chronic hand eczema with an inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled proof of concept efficacy study
    Medical condition: Hand eczema
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10066695 Chronic hand dermatitis LLT
    20.0 100000004858 10036145 Pompholyx eczema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Aug 19 10:11:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA